These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 12479593)
1. Treatment of aggressive non-Hodgkin's lymphoma with chemotherapy in combination with filgrastim. Schriber J Drugs; 2002; 62 Suppl 1():33-46. PubMed ID: 12479593 [TBL] [Abstract][Full Text] [Related]
2. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma. Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178 [TBL] [Abstract][Full Text] [Related]
3. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609 [TBL] [Abstract][Full Text] [Related]
4. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W; Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651 [TBL] [Abstract][Full Text] [Related]
5. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. Lee SM; Radford JA; Dobson L; Huq T; Ryder WD; Pettengell R; Morgenstern GR; Scarffe JH; Crowther D Br J Cancer; 1998 Apr; 77(8):1294-9. PubMed ID: 9579836 [TBL] [Abstract][Full Text] [Related]
6. Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lumphoma. Corato A; Ambrosetti A; Rossi B; Vincenzi C; Lambiase A; Perona G; Pizzolo G; de Wynter E; Nadali G J Hematother Stem Cell Res; 2000 Oct; 9(5):673-82. PubMed ID: 11091491 [TBL] [Abstract][Full Text] [Related]
7. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. Scott SD; Chrischilles EA; Link BK; Delgado DJ; Fridman M; Stolshek BS J Manag Care Pharm; 2003; 9(2 Suppl):15-21. PubMed ID: 14613340 [TBL] [Abstract][Full Text] [Related]
8. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Demuynck HM; Link H; Zander A; Barge A Lancet; 1996 Feb; 347(8998):353-7. PubMed ID: 8598700 [TBL] [Abstract][Full Text] [Related]
9. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease. Silvestri F; Fanin R; Velisig M; Barillari G; Virgolini L; Zaja F; Russo D; Baccarani M Tumori; 1994 Dec; 80(6):453-8. PubMed ID: 7534963 [TBL] [Abstract][Full Text] [Related]
10. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group. Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465 [TBL] [Abstract][Full Text] [Related]
11. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma. Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266 [TBL] [Abstract][Full Text] [Related]
12. Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes? Gregory SA; Trümper L Ann Oncol; 2005 Sep; 16(9):1413-24. PubMed ID: 15932900 [TBL] [Abstract][Full Text] [Related]
13. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118 [TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. Doorduijn JK; Buijt I; van der Holt B; van Agthoven M; Sonneveld P; Uyl-de Groot CA Haematologica; 2004 Sep; 89(9):1109-17. PubMed ID: 15377472 [TBL] [Abstract][Full Text] [Related]
15. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma. Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500 [TBL] [Abstract][Full Text] [Related]
16. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis. Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930 [TBL] [Abstract][Full Text] [Related]
17. Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high-intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin's lymphoma: an oligocentric report on 42 patients. Bouabdallah R; Stoppa AM; Rossi JF; Lepeu G; Coso D; Xerri L; Ladaique P; Chabannon C; Blaise D; Bardou VJ; Alzieu C; Gastaut JA; Maraninchi D Leukemia; 1999 Jun; 13(6):950-6. PubMed ID: 10360385 [TBL] [Abstract][Full Text] [Related]
18. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma. Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783 [TBL] [Abstract][Full Text] [Related]
19. A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study. Davidson KL; Devaney MB; Tighe JE; Rogers SY; Dunlop DJ; Mackie MJ; Thomas RV; Johnson PR; Haematologica; 2003 Dec; 88(12):1366-71. PubMed ID: 14687989 [TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma. Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]